TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 years old~* Mild to moderate unilateral, symptomatic osteoarthritis of the knee~* No recent (within 3 months) intra-articular intervention to the affected knee~Exclusion Criteria:~* Knee instability~* Varus/Valgus alignment \>5 degrees~* Bilateral knee osteoarthritis~* Systemic inflammatory arthropathy~* Known history of anemia, coagulopathy, or present use of blood thinners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Hyaluronic Acid (HA) (Type: ACTIVE_COMPARATOR): Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
- Platelet-rich Plasma (PRP) (Type: EXPERIMENTAL): Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy adults between the age of 18 and 40 years~2. Visual acuity of 20/20 with corrected vision~Exclusion Criteria:~1. History of neurological condition (i.e. stroke, Alzheimer's disease, Parkinson's disease), Attention Deficit Hyperactivity Disorder (ADHD), depression, bipolar disorder, balance impairment, or vestibular disorder~2. History of severe motion sickness, moderate to severe motion sickness or nausea on oculo-motor components of Simulator sickness questionnaire, inability to ride a car, boat, train or airplane due to motion sickness~3. Recent wrist, hand or forearm injury that would currently prevent ability to lift weights~4. History of lower extremity condition, injury, or surgery that would currently impair ability to stand or balance~5. Any extremity soft tissue, orthopedic, or vascular injury (i.e. peripheral vascular disease) which may contraindicate RLIC~6. Any cognitive, sensory, or communication problem that would prevent completion of the study~7. History of or current sleep apnea~8. Current intensive weight lifting or interval training exercise~9. Current substance abuse or dependence~10. Unwillingness to travel for all study visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Remote Limb Ischemic Conditioning (RLIC) (Type: EXPERIMENTAL): RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
- Sham Conditioning (Type: SHAM_COMPARATOR): Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic myeloma diagnosis according to criteria in attachment 3~* ASCT is performed or has been performed in the last five weeks (time limit two weeks for patients randomised at 2nd transplantation) as a part of primary therapy~* Signed informed consent given prior to any study related activities have been performed~Exclusion Criteria:~* Prior exposure to bortezomib~* Allogeneic transplantation scheduled as a part of the primary treatment~* Neuropathy \> Grade 2 (neurological symptoms interfering with ADL)~* Non-secreting myeloma~* Other concurrent disease making bortezomib treatment unsuitable~* Positive pregnancy test (only applicable for women with childbearing potential)~* Has known or suspected hypersensitivity or intolerance to boron, mannitol, or heparin, if an indwelling catheter is used~* Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure (Attachment 6, NYHA Classification of Cardiac Disease), uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis~* History of hypotension or has decreased blood pressure (sitting systolic blood pressure \[SBP\] £100 mmHg and/or sitting diastolic blood pressure \[DBP\] £60 mmHg)~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Have received an experimental drug or used an experimental medical device within 4 weeks prior to inclusion into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No treatment (Type: ACTIVE_COMPARATOR): None
- Bortezomib consolidation (Type: EXPERIMENTAL): Bortezomib consolidation : 20 injections starting 3 months after ASCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a clinical diagnosis of acute ischemic stroke,~* caused by a large vessel occlusion of the anterior circulation (distal intracranial carotid artery or middle M1/proximal M2) cerebral artery confirmed by CTA,~* CT or MRI ruling out intracranial hemorrhage,~* eligible for IVT and IAT (within 4.5 hours after symptom onset),~* a score of at least 2 on the NIH Stroke Scale,~* age of 18 years or older,~* written informed consent.~Exclusion Criteria:~* - Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS \>2~* Any contra-indication for IVT, according to guidelines of the American Heart Association, i.e.:~  * arterial blood pressure exceeding 185/110 mmHg~ * blood glucose less than 2.7 or over 22.2 mmol/L~ * cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging~ * serious head trauma in the previous 3 months~ * major surgery or serious trauma in the previous 2 weeks~ * gastrointestinal or urinary tract hemorrhage in the previous 3 weeks~ * previous intracerebral hemorrhage~ * use of anticoagulant with INR exceeding 1.7~ * known thrombocyte count less than 100 x 109/L~ * treatment with direct thrombin or factor X inhibitors~ * treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Direct MT (Type: SHAM_COMPARATOR): Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
- IVT combine with MT (Type: ACTIVE_COMPARATOR): Intravenous thrombolysis before mechanical thrombectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 24 males will be included in the study recruited from Andrology, Sexology \& STD's outpatient clinic, Kasr El Aini Hospitals, Cairo University, complaining of Vascular ED proved by penile duplex.~* Unable to develop erections sufficient for intercourse.~* Failing to respond to first line and second line treatments for Erectile Dysfunction with surgery as the only remaining treatment option.~* Age between 40 to 70 years.~Exclusion Criteria:~* Significant cardiovascular disease interfering with sexual activity

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- (BTX) A Group (Type: EXPERIMENTAL): The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
- Saline Group (Type: PLACEBO_COMPARATOR): The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescent (ages 10 - 17 years) boys or girls weighing at least 88 lbs (40 kg).~* Subjects must have high cholesterol (low density lipoprotein cholesterol \[LDL-C\] more than 159 mg/dL or 4.1 mmol/L) and a family history of high cholesterol.~Exclusion Criteria:~* Subjects diagnosed with delayed puberty.~* Subjects who are sensitive to simvastatin and/or ezetimibe.~* Subjects who drink alcohol excessively or who have a history of alcohol or drug abuse within the past 2 years.~* Subjects who are known to be HIV positive, are undergoing LDL apheresis or plasma apheresis, or have had a partial ileal bypass.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pooled subjects who received ezetimibe with simvastatin (Type: EXPERIMENTAL): Pooled subjects who received ezetimibe 10 mg plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg
- Pooled subjects who received simvastatin monotherapy (Type: ACTIVE_COMPARATOR): Pooled subjects who received ezetimibe matching placebo plus simvastatin 10 mg, simvastatin 20 mg, or simvastatin 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* out-patients children with diagnosis of functional constipation or have faecal impaction on medical history and physical examination~Exclusion Criteria:~* children with organic causes for defecation disorders, such as Hirschsprung disease, spina bifid, hypothyroidism, or other metabolic or renal abnormalities;~* Children receiving medication influencing gastrointestinal motility;~* Children with suspected gastrointestinal obstruction or stenosis

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- PEG-only (Type: EXPERIMENTAL): Polyethylene glycol 4000 only (PEG-only).
- PEG-EL (Type: ACTIVE_COMPARATOR): Polyethylene glycol 3350 with electrolytes (PEG-EL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed the core study (IGE025B1301) and who in the investigator's clinical judgment could benefit from continuous treatment of the study drug.~Exclusion Criteria:~* Patients who currently have diagnosed cancer, are currently being investigated for possible cancer or have any history of cancer.~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means; using a highly effective method of birth control; or agreeing on total abstinence and the investigator also judges that the age, career lifestyle or sexual orientation of the patient ensures compliance.~* With clinically significant uncontrolled systemic disease (eg: infection, hematological disease, renal, hepatic, coronary heart disease or other cardiovascular disease, cerebro-vascular, endocrinologic or gastrointestinal disease) after the treatment period of the core study.~* Patients with a history of major protocol violations during the core study and who are considered potentially unreliable as judged by the investigator at each site.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic multiple myeloma, ISS stages I-III, within 12 months of starting therapy.~* Completion of induction therapy with Very Good Partial Response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria.~* Deemed eligible for ASCT by standard institutional criteria.~* Age ≥18 years.~* Documentation of CT7, MAGE-A3, or WT1 expression in the bone marrow and/or bone marrow aspirate.~Exclusion Criteria:~* Prior autologous or allogeneic SCT.~* Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1.~* Known immunodeficiency, HIV positivity, hepatitis B, or hepatitis C.~* History of autoimmune disease (e.g., rheumatoid arthritis, SLE), other than vitiligo, diabetes, or treated thyroiditis, which are allowed.~* History of severe allergic reactions to vaccines or unknown allergens.~* Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first immunization.~* Lenalidomide-related toxicities before ASCT necessitating its discontinuation as part of treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Vaccine (Type: EXPERIMENTAL): This is a prospective, two-arm phase I randomized trial. Patients will be accrued only from and treated at MSKCCand The Rockefeller University/Center for Clinical \& Translational Science . The study will assess autologous LCs presenting CT7, MAGE-A3, and WT1 after electroporation with CT7, MAGE-A3, and WT1 mRNA. Twenty patients will accrue to the study and ten will receive vaccines at 9x10\^6 LCs per dose (i.e., combination of 3x10\^6 CT7 mRNA-electroporated LCs + 3x10\^6 MAGE-A3 mRNA-electroporated LCs + 3x10\^6 WT1 mRNA-electroporated LCs) and another ten who will not receive any LC vaccines but will otherwise undergo identical cytoreduction, ASCT, and standard supportive care. At approximately 3 months after ASCT and as deemed clinically appropriate, patients will start lenalidomide maintenance therapy, which is now standard to delay disease progression.
- Arm 2 control (Type: ACTIVE_COMPARATOR): Patients receive standard of care treatment after autologous stem cell transplant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Elevated IOP due to either primary open-angle glaucoma or ocular hypertension~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimatoprost 0.01% (Naive Monotherapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
- Bimatoprost 0.01% (Switched Monotherapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
- Bimatoprost 0.01% (with Adjunctive Therapy) (Type: EXPERIMENTAL): 1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* Subjects must have been diagnosed with irritable bowel syndrome by a physician~* Subjects must have had gastrointestinal symptoms for 2 or more days per week for \> 6 months~Exclusion Criteria:~* Lifetime history of bipolar disorder, psychotic disorder, or obsessive-compulsive disorder~* Current (within past 6 months) diagnosis of major depressive disorder or substance abuse disorder~* Active suicidal/homicidal ideation~* Pregnant women or women of child-bearing potential not using an approved methods of contraception~* Individuals with an unstable medical condition that in the opinion of the investigator would interfere with the interpretation of symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): 12-week, open-label trial of duloxetine in subjects with IBS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥ 18 years old.~2. Medical record documentation of either: a) a current diagnosis or history of recurrent CDI as determined by the treating physician, b) or has had at least two episodes of severe CDI resulting in hospitalization.~3. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at the time of enrollment. \[Note: Subject's CDI diarrhea must be controlled (\<3 unformed/loose stools/day) while taking antibiotics during screening.\]~Exclusion Criteria:~1. Has continued CDI diarrhea despite being on a course of antibiotics prescribed for CDI treatment.~2. Requires systemic antibiotic therapy for a condition other than CDI.~3. Fecal microbiota transplant (FMT) within the past 6 months.~4. FMT with an associated serious adverse event related to the FMT product or procedure.~5. Bezlotoxumab (CDI monoclonal antibodies) if received within the last year.~6. CD4 count \<200/mm\^3 during Screening.~7. An absolute neutrophil count of \<1000 cells/µL during Screening.~8. Pregnant, breastfeeding, or intends to become pregnant during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): RBX2660 is an enema of a microbiota suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete